同源重组修复相关Rad51在肿瘤中的研究进展
|
摘要
Rad51基因的突变在很多方面发挥着很关键的作用,比如抑制多种肿瘤的发生与发展,以及肿瘤对放疗和化疗药物的耐药性等方面。另外,由于Rad51基因是DNA修复基因,其在维持基因的稳定性方面有着极其重要的作用。而且,Rad51基因可能也会在肿瘤的发生、发展中与其他基因相互作用对其产生影响。本文主要对同源重组修复相关Rad51在肿瘤中的研究进展作一综述。
Rad51 gene mutation plays a key role in many aspects,such as inhibiting the occurrence and development of a variety of tumors,and tumor resistance to radiotherapy and chemotherapy drugs.In addition,as Rad51 gene is a DNA repair gene,it plays an extremely important role in maintaining gene stability.In addition,Rad51 gene may also interact with other genes in the occurrence and development of tumors.This review focuses on the research progress of homologous recombination repair related Rad51 in tumors.
Rad51 gene mutation plays a key role in many aspects,such as inhibiting the occurrence and development of a variety of tumors,and tumor resistance to radiotherapy and chemotherapy drugs.In addition,as Rad51 gene is a DNA repair gene,it plays an extremely important role in maintaining gene stability.In addition,Rad51 gene may also interact with other genes in the occurrence and development of tumors.This review focuses on the research progress of homologous recombination repair related Rad51 in tumors.
引文
[1]闫芸芳,龙腾飞,周家德.卵巢癌中Rad51蛋白表达的意义[J].安徽医学,2014,35(1):23-26.
[2]冯书云,杜鸿志,黄悦,等.靶向Rad51与肿瘤治疗的研究进展[J].现代生物医学进展,2017,17(15):2993-2995.
[3]彭亚婷,梅金红.Rad51与肿瘤关系的研究进展[J].临床与实验病理学杂志,2011,27(1):86-89.
[4]孟盟.Rad51 BRCA2在卵巢癌中的研究进展[J].内蒙古医学杂志,2014,46(8):948-951.
[5]Tennstedt P,Fresow R,Simon R,et al.RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma[J].International Journal of Cancer Journal International du Cancer,2013,9(9):2118-2126.
[6]闫芸芳.Rad51在卵巢癌中的研究进展[J].现代妇产科进展,2013,22(9):762-764.
[7]刘浩,尹华斌,纪方.Micro RNA与肿瘤的相关研究进展[J].现代生物医学进展,2012,12(7):1388-1390.
[8]Neijenhuis S,Bajrami I,Miller R,et al.Identification of miRNAmodulators to PARP inhibitor response[J].DNA repair,2013,6(6):394-402.
[9]Wang Y,Huang J W,Calses P,et al.MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition[J].Cancer research:The official organ of the American Association for Cancer Research,2012,16(16):4037-4046.
[10]赵欣,李媛媛,曹丁丁,等.肿瘤表观基因组学研究进展[J].现代生物医学进展,2016,(1):172-175,183.
[11]Tibes R,Fine G,Choy G,et al.A phase I,first-in-human doseescalation study of amuvatinib,a multi-targeted tyrosine kinase inhibitor,in patients with advanced solid tumors[J].Cancer Chemotherapy and Pharmacology,2013,2(2):463-471.
[12]周化民,孙旭利,陈建明.同源重组和重组酶Rad51的调控[J].生物化学与生物物理进展,2016(12):1154-1162.
[13]王晓琳,饶本强,江波,等.生酮饮食联合疗法治疗恶性肿瘤研究进展[J/OL].肿瘤代谢与营养电子杂志,2016,3(4):255-260.
[14]许俊,高俊,陈洪雷.DNA修复基因Rad51和ERCC1蛋白在人肺鳞癌中的表达意义[J].医学研究杂志,2011,40(3):31-34.
[15]王奕丹,章建国,田薇,等.脑胶质瘤中Rad 51及端粒酶逆转录酶的表达研究[J].现代预防医学,2013,40(21):4015-4018.
[16]Parsels L A,Morgan M A,Tanska D M,et al.Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51DNA damage response in pancreatic cancer cells[J].Mol Cancer Ther,2009,8(1):45-54.
[17]杨丽,师长宏,赵勇,等.卡介苗Hsp16.3基因突变株对小鼠巨噬细胞RAW264.7自噬的影响[J].科学技术与工程,2016,16(23):7-12,34.
[18]李静,张艳亮,段勇.miRNAs表达谱在肺肿瘤中的临床应用[J].检验医学与临床,2016,13(9):214-217.
[19]Hine C M,Seluanov A,Gorbunova V,et al.Use of the Rad51 promoter for targeted anti-cancer therapy[J].Proc Natl Acad Sci USA,2008,105(52):20810-20820.
[20]乔贵宾,曾伟生,彭丽君,等.Rad51在非小细胞肺癌中的作用及其预后作用[J].中华肿瘤防治杂志,2009,16(14):1086-1090.
[21]Shammas M A,Shmookler R R J,Koley H,et al.Dysfunc-tional homologous recombination mediates genomic instability and progression in myeloma[J].Blood,2009,113(10):2290-2297.
[22]Kuznetsov S G,Haines D C,Martin B K,et al.Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice[J].Cancer Res,2009,69(3):863-872.
[23]Riches L C,Lynch A M,Gooderham N J.Early events in the mammalian response to DNA double-strand breaks[J].Muta-genesis,2008,23(5):331-339.
[24]王阁,毛必静.miRNAs参与肝细胞肝癌发生机制的探索与临床应用的挑战[J].世界华人消化杂志,2016,23(33):324-327.
[25]孙嘉玲,文彬,孙海涛,等.miRNAs与肝细胞癌的相关性研究进展[J].中国药理学通报,2017,13(4):178-181.
[26]曾勇,李娜,王福花,等.卵巢浆液性囊腺癌化疗耐药和化疗敏感组织中的mi RNAs差异表达谱检测及生物信息学分析[J].现代肿瘤医学,2017,11(12):233-237.
[27]田艳,冼乐武,韦伊尔.吉非替尼诱导前后肺癌干细胞miRNAs的表达差异[J].广东医学,2017,12(9):193-195.
[28]郁成雨,潘真,王春刚,等.RNA干扰抑制RAD51基因表达对放射敏感性影响的实验研究[J].中华肿瘤防治杂志,2006,13(24):1852-1855.
[29]陈汉春,彭兴华.Rad51同系物与DNA重组修复[J].国外医学:遗传学分册,2003,26(4):194-197.
[30]黄敏,杨业然,孙晓艳,等.RAD51调控REV1参与DNA双链断裂修复[J].遗传,2018,40(11):1007-1014.
[2]冯书云,杜鸿志,黄悦,等.靶向Rad51与肿瘤治疗的研究进展[J].现代生物医学进展,2017,17(15):2993-2995.
[3]彭亚婷,梅金红.Rad51与肿瘤关系的研究进展[J].临床与实验病理学杂志,2011,27(1):86-89.
[4]孟盟.Rad51 BRCA2在卵巢癌中的研究进展[J].内蒙古医学杂志,2014,46(8):948-951.
[5]Tennstedt P,Fresow R,Simon R,et al.RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma[J].International Journal of Cancer Journal International du Cancer,2013,9(9):2118-2126.
[6]闫芸芳.Rad51在卵巢癌中的研究进展[J].现代妇产科进展,2013,22(9):762-764.
[7]刘浩,尹华斌,纪方.Micro RNA与肿瘤的相关研究进展[J].现代生物医学进展,2012,12(7):1388-1390.
[8]Neijenhuis S,Bajrami I,Miller R,et al.Identification of miRNAmodulators to PARP inhibitor response[J].DNA repair,2013,6(6):394-402.
[9]Wang Y,Huang J W,Calses P,et al.MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition[J].Cancer research:The official organ of the American Association for Cancer Research,2012,16(16):4037-4046.
[10]赵欣,李媛媛,曹丁丁,等.肿瘤表观基因组学研究进展[J].现代生物医学进展,2016,(1):172-175,183.
[11]Tibes R,Fine G,Choy G,et al.A phase I,first-in-human doseescalation study of amuvatinib,a multi-targeted tyrosine kinase inhibitor,in patients with advanced solid tumors[J].Cancer Chemotherapy and Pharmacology,2013,2(2):463-471.
[12]周化民,孙旭利,陈建明.同源重组和重组酶Rad51的调控[J].生物化学与生物物理进展,2016(12):1154-1162.
[13]王晓琳,饶本强,江波,等.生酮饮食联合疗法治疗恶性肿瘤研究进展[J/OL].肿瘤代谢与营养电子杂志,2016,3(4):255-260.
[14]许俊,高俊,陈洪雷.DNA修复基因Rad51和ERCC1蛋白在人肺鳞癌中的表达意义[J].医学研究杂志,2011,40(3):31-34.
[15]王奕丹,章建国,田薇,等.脑胶质瘤中Rad 51及端粒酶逆转录酶的表达研究[J].现代预防医学,2013,40(21):4015-4018.
[16]Parsels L A,Morgan M A,Tanska D M,et al.Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51DNA damage response in pancreatic cancer cells[J].Mol Cancer Ther,2009,8(1):45-54.
[17]杨丽,师长宏,赵勇,等.卡介苗Hsp16.3基因突变株对小鼠巨噬细胞RAW264.7自噬的影响[J].科学技术与工程,2016,16(23):7-12,34.
[18]李静,张艳亮,段勇.miRNAs表达谱在肺肿瘤中的临床应用[J].检验医学与临床,2016,13(9):214-217.
[19]Hine C M,Seluanov A,Gorbunova V,et al.Use of the Rad51 promoter for targeted anti-cancer therapy[J].Proc Natl Acad Sci USA,2008,105(52):20810-20820.
[20]乔贵宾,曾伟生,彭丽君,等.Rad51在非小细胞肺癌中的作用及其预后作用[J].中华肿瘤防治杂志,2009,16(14):1086-1090.
[21]Shammas M A,Shmookler R R J,Koley H,et al.Dysfunc-tional homologous recombination mediates genomic instability and progression in myeloma[J].Blood,2009,113(10):2290-2297.
[22]Kuznetsov S G,Haines D C,Martin B K,et al.Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice[J].Cancer Res,2009,69(3):863-872.
[23]Riches L C,Lynch A M,Gooderham N J.Early events in the mammalian response to DNA double-strand breaks[J].Muta-genesis,2008,23(5):331-339.
[24]王阁,毛必静.miRNAs参与肝细胞肝癌发生机制的探索与临床应用的挑战[J].世界华人消化杂志,2016,23(33):324-327.
[25]孙嘉玲,文彬,孙海涛,等.miRNAs与肝细胞癌的相关性研究进展[J].中国药理学通报,2017,13(4):178-181.
[26]曾勇,李娜,王福花,等.卵巢浆液性囊腺癌化疗耐药和化疗敏感组织中的mi RNAs差异表达谱检测及生物信息学分析[J].现代肿瘤医学,2017,11(12):233-237.
[27]田艳,冼乐武,韦伊尔.吉非替尼诱导前后肺癌干细胞miRNAs的表达差异[J].广东医学,2017,12(9):193-195.
[28]郁成雨,潘真,王春刚,等.RNA干扰抑制RAD51基因表达对放射敏感性影响的实验研究[J].中华肿瘤防治杂志,2006,13(24):1852-1855.
[29]陈汉春,彭兴华.Rad51同系物与DNA重组修复[J].国外医学:遗传学分册,2003,26(4):194-197.
[30]黄敏,杨业然,孙晓艳,等.RAD51调控REV1参与DNA双链断裂修复[J].遗传,2018,40(11):1007-1014.